Key Highlights

• The FY26 numbers set a high base, and management has guided to another year of organic growth and Margin expansion, so the half-year result will show whether momentum is holding.

• Life Sciences covers food, pharmaceutical, environmental and related testing, and accounted for about 61 per cent of group Revenue in FY26.

• Underlying EBIT rose 19.3 per cent to A$599 million, and the EBIT margin widened to 18.0 per cent.

• Underlying net profit after tax was A$381.2 million, up 25.8 per cent, and underlying Earnings Per Share were 75.7 cents.

What is driving the renewed interest in ALS Limited (ASX:ALQ)? The testing group has just reported record earnings for the year ended 31 March 2026, helped by encouraging Demand for geochemistry and minerals analysis, and it is due to report its first-half FY27 result on 23 November 2026.

The FY26 numbers set a high base, and management has guided to another year of organic growth and margin expansion, so the half-year result will show whether momentum is holding.

What ALS does and how it earns revenue

ALS provides laboratory testing and inspection services across two broad divisions. Commodities covers testing for the Mining and resources sector, including minerals, geochemistry, metallurgy and industrial materials. Life Sciences covers food, pharmaceutical, environmental and related testing, and accounted for about 61 per cent of group revenue in FY26.

Revenue is largely tied to sample volumes and the number and complexity of tests. In Commodities, that makes exploration and mine-site activity the key driver, while Life Sciences is more closely linked to regulation, food safety, environmental compliance and pharmaceutical development.

The FY26 result

Underlying EBIT rose 19.3 per cent to A$599 million, and the EBIT margin widened to 18.0 per cent. Underlying net profit after tax was A$381.2 million, up 25.8 per cent, and underlying earnings per share were 75.7 cents.

Free Cash Flow was A$674 million, up 14 per cent, and return on Capital employed improved to 21.5 per cent. Net interest expense fell to A$69.3 million from A$81.7 million.

The combined FY26 Dividend was 42.5 cents per share, about 10 per cent higher, equal to a payout of roughly 57 per cent of underlying profit. The final dividend was 23.1 cents, franked at 30 per cent.

Commodities leads the growth

Commodities revenue was A$1.29 billion, up 18.8 per cent, with organic growth of 17.9 per cent and an EBIT margin of 29.5 per cent. Within it, minerals organic growth was 20.2 per cent at a margin of 33 per cent, and geochemistry grew 22.7 per cent organically. Industrial Materials grew 10.5 per cent, while metallurgy declined 2.5 per cent.

Life Sciences revenue rose about 6 per cent, but organic growth was 2.8 per cent and the EBIT margin was 14.6 per cent. Food testing grew 7.2 per cent organically, pharma fell 1.6 per cent, and environmental testing was mixed, with mid-single-digit growth in Asia-Pacific and Europe, the Middle East and Africa but weaker results in the Americas.

Integration issues and balance sheet

Management described the York Acquisition as the main integration challenge. Lost certifications and subcontracting costs weighed on results, although certifications were reinstated in the fourth quarter. The Nuvisan pharma Business completed its transformation, with about 25 million euros in exit savings, and Wessling was reported as ahead of its business case.

Leverage fell to 1.5 times, below the company's 1.7 to 2.3 times target range, helped by earnings growth and the A$367 million Equity raising completed in May 2025. Liquidity exceeded A$580 million, including about A$530 million of undrawn committed facilities, and the weighted average Debt Maturity was 3.9 years.

Capital expenditure was A$263 million, including about A$94 million for hub laboratories.

FY27 guidance and recent announcements

For FY27, ALS guided to mid-to-high single-digit organic revenue growth for the group, with margin expansion at a similar pace to FY26. In minerals, it expects organic growth of 13 to 15 per cent, with first-half growth of 15 to 17 per cent. Industrial Materials is expected to grow at a high single-digit rate, and Life Sciences at an improved mid-single-digit rate.

Other guided items include base Capital Expenditure of about A$170 million plus about A$70 million for hub laboratories, interest costs of A$65 million to A$67 million, and corporate costs of about 2.3 per cent of revenue. Management also flagged an earnings impact of A$5 million to A$10 million from the Middle East.

At the July 2026 annual general meeting, the company said it had reached its FY27 strategic targets a year early.

Sector conditions and competitive position

Demand for minerals testing generally follows exploration budgets, which depend on Commodity prices and financing conditions for explorers and miners. ALS operates globally and competes with other international laboratory groups and regional operators in each segment. Because ALS reports in Australian dollars and operates globally, currency moves also affect its earnings.

Integration quality matters for the acquired Life Sciences businesses, as the York experience shows.

Risks and what to watch

The key uncertainty is whether encouraging minerals sample volumes persist. A slowdown in exploration spending would affect the segment that drove FY26 growth. Currency also matters: management estimates that a 1 per cent move in major currencies against the Australian dollar changes EBIT by about A$3 million and net profit by about A$2 million.

Other risks include further integration problems in York and the Americas environmental business, the Middle East impact, and a cyber incident that was reported as contained. Management said it did not expect a material financial impact, although the investigation was continuing at the time of the results.

The first-half FY27 result on 23 November 2026, which is subject to change, will be the next test of the guidance. Investors will likely focus on minerals growth, margins and Life Sciences organic growth.